Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
about
Evaluation of the likelihood of a selective CHK1 inhibitor (LY2603618) to inhibit CYP2D6 with desipramine as a probe substrate in cancer patients.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Evaluation of the likelihood o ...... substrate in cancer patients.
@en
Evaluation of the likelihood of a selective CHK1 inhibitor
@nl
type
label
Evaluation of the likelihood o ...... substrate in cancer patients.
@en
Evaluation of the likelihood of a selective CHK1 inhibitor
@nl
prefLabel
Evaluation of the likelihood o ...... substrate in cancer patients.
@en
Evaluation of the likelihood of a selective CHK1 inhibitor
@nl
P2093
P2860
P356
P1476
Evaluation of the likelihood o ...... substrate in cancer patients.
@en
P2093
Enaksha Wickremsinhe
Jason Chandler
Jennifer Ott
Malcolm Mitchell
Rodney Decker
Scott M Hynes
P2860
P356
10.1002/BDD.1922
P577
2014-11-14T00:00:00Z